MergerJul 22, 2026, 05:21 PM
Repligen to Acquire BioLife Solutions for $1.5B, $31/Share
AI Summary
Repligen Corporation has entered into a definitive agreement to acquire BioLife Solutions, Inc. for a total enterprise value of approximately $1.5 billion. BioLife stockholders will receive $11.25 in cash and 0.1442 shares of Repligen common stock per share, valuing the transaction at $31.00 per share, representing a 24% premium. The acquisition is expected to close in Q4 2026 and is projected to be accretive to Repligen's adjusted EPS by at least $0.05 in year one and $0.25 in year two, with anticipated synergies of $20-30 million. Both companies also released preliminary unaudited second-quarter 2026 revenue figures.
Key Highlights
- Repligen to acquire BioLife Solutions for approximately $1.5 billion enterprise value.
- BioLife stockholders to receive $31.00 per share ($11.25 cash, 0.1442 Repligen stock).
- The offer represents an implied premium of 24% to BioLife's 90-day VWAP.
- Transaction expected to close in Q4 2026, subject to approvals.
- Expected to be accretive to Repligen's adjusted EPS by at least $0.05 in year one and $0.25 in year two.
- Repligen anticipates at least $20 million in synergies in year one, $30 million in year two.
- Repligen reported preliminary Q2 2026 revenue growth of 12% reported, 13% organic.
- BioLife reported preliminary Q2 2026 revenue of $28.5 million, up 21% year-over-year.
Price Impact
More from BLFS